ALEMG.PA • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALEMG.PA in your mock portfolio yet.
With EPS of €0.15 and a PE ratio of 26.20, Euromedis Groupe is priced at a moderate earnings multiple that implies some growth expectations but not deep value. The current valuation appears neither clearly cheap nor excessively expensive given the limited earnings information provided. Profitability exists but does not appear strong enough to justify a decisively bullish stance without evidence of accelerating growth.
The stock trades at €3.93, slightly below its 200‑day moving average of €4.03, pointing to a mildly negative intermediate trend. The RSI at 35.16 is near but not yet in oversold territory, suggesting some recent selling pressure but no capitulation. The modest 0.5% decline over the last month indicates consolidation rather than a strong downtrend or rebound.
Zero current job openings and no month‑over‑month increase point to a lack of visible expansion or hiring momentum. A small LinkedIn following of 962 suggests limited brand reach, investor attention, or employer visibility in public channels. Together, these signals lean slightly negative for near‑term growth and market interest.
Overall, Euromedis Groupe presents a balanced risk‑reward profile with modest profitability, a middling valuation, and slightly soft technicals. The lack of hiring momentum and limited social media presence are mild negatives, but the stock is not in a clear technical downtrend nor obviously overvalued. On current information, the outlook appears neutral, with the next move likely dependent on future earnings growth or clearer operational catalysts.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: